Get started

Financials · RMTI

Rockwell Medical Inc. (RMTI) financials

For the twelve months ended Jun 30, 2026, Rockwell Medical Inc. reported $69.39M of revenue and -$5.08M of net income.

Revenue, TTM
$69.39M
Revenue growth, YoY
-21.1%
Net income, TTM
-$5.08M
Net margin
-7.3%
Free cash flow, TTM
$1.54M
Cash
$10.52M
Total debt
$9.00M
P/S
0.44
Market cap
$30.3M
Annual revenue$69.26M
FY2017FY2025
Annual net income-$5.31M
FY2016FY2025
Annual free cash flow-$1.20M
FY2023FY2025

RMTI revenue and earnings growth

RMTI revenueQ2 2026$17.78M

Quarter YoY
+10.6%
QoQ
+2.6%
FY YoY
-31.8%
5Y CAGR
+2.2%

RMTI revenue was $17.78M in fiscal Q2 2026 (ended Jun 30, 2026), up 10.6% from a year earlier and up 2.6% from the prior quarter. For the full fiscal 2025 it was $69.26M, down 31.8% from fiscal 2024. Compound annual growth was +2.2% over 5 years. It rose in 5 of the last 8 fiscal years.

RMTI net incomeQ2 2026-$1.17M

RMTI net income was -$1.17M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.49M a year earlier. For the full fiscal 2025 it was -$5.31M, compared with -$480.0K in fiscal 2024.

RMTI EPSQ1 2026-$0.04

RMTI diluted EPS was -$0.04 in fiscal Q1 2026 (ended Mar 31, 2026), compared with -$0.04 a year earlier. For the full fiscal 2025 it was -$0.15, compared with -$0.03 in fiscal 2024.

RMTI free cash flowQ2 2026$1.46M

Quarter YoY
-12.9%

RMTI free cash flow was $1.46M in fiscal Q2 2026 (ended Jun 30, 2026), down 12.9% from a year earlier. For the full fiscal 2025 it was -$1.20M, compared with $3.19M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$69.26M$101.49M$83.61M$72.81M$61.93M$62.20M$61.30M$63.39M$57.30M-
Cost of revenue$57.56M$84.00M$74.91M$68.73M$64.35M$59.47M$58.46M$64.97M$53.60M$46.53M
Gross profit$11.70M$17.48M$8.70M$4.08M-$2.42M$2.73M$2.84M-$1.58M$3.70M$6.75M
Research and development$0$19.0K$1.11M$3.12M$6.83M$7.09M$6.89M$5.64M$6.32M$5.84M
Selling, general and admin$14.03M$14.11M$12.14M$15.64M$15.35M$16.18M$21.00M$22.08M$23.30M$21.12M
Operating income-$4.69M$608.0K-$6.67M-$16.78M-$30.34M-$28.42M-$34.52M-$32.44M-$25.92M-$20.21M
Interest expense$1.12M$1.25M$2.30M$1.94M$2.36M$1.88M$25.0K---
Pre-tax income-$5.31M-$480.0K-$8.44M------$25.92M-$19.40M
Income tax$0$0$0$0$0$0$0$0$0$404.5K
Net income-$5.31M-$480.0K-$8.44M-$18.68M-$32.67M-$30.89M-$34.13M-$32.13M-$25.92M-$19.80M
EPS, basic-$0.15-$0.03-$0.37-$1.31-$3.83-$4.51-$6.16-$6.71-$5.61-$4.29
EPS, diluted-$0.15-$0.03-$0.37-$1.31-$3.83-$4.51-$6.16-$6.71-$5.61-$4.29
Diluted shares36.0M31.1M23.3M14.3M8.5M6.9M5.5M4.8M4.6M4.6M

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$10.71M$15.66M$8.98M$10.10M$13.28M$48.68M$11.79M$22.71M$8.41M$17.18M
Receivables$8.14M$8.29M$10.90M$6.26M$5.91M$4.17M$4.20M$6.98M$6.36M$6.39M
Inventory$3.42M$5.78M$5.87M$5.81M$4.08M$3.91M$3.65M$4.04M$7.64M$12.14M
Current assets$38.16M$37.03M$28.77M$35.31M$35.29M$69.47M$36.87M$46.83M$48.83M$78.51M
Goodwill$921.0K$921.0K$921.0K$921.0K$921.0K$921.0K$921.0K$920.7K$920.7K$920.7K
Total assets$57.15M$59.21M$52.17M$46.63M$48.57M$77.75M$44.32M$52.56M$58.78M$83.15M
Current liabilities$9.58M$14.09M$16.64M$17.69M$20.97M$12.79M$12.37M$13.20M$9.14M$10.15M
Short-term debt$0-$0$1.63M$7.38M$0----
Long-term debt$8.83M$8.47M$8.29M$7.55M$13.19M$20.95M$0---
Total debt$8.83M$8.47M$8.29M$9.19M$20.57M$20.95M$0$0--
Total liabilities$20.16M$26.62M$30.88M$32.53M$46.04M$43.58M$24.00M$25.28M$25.87M-
Shareholders' equity$36.98M$32.59M$21.29M$14.11M$2.54M$34.17M$20.32M$27.28M$32.91M$52.96M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$659.0K$4.20M-$9.41M-$16.93M-$33.53M-$29.64M-$27.25M-$20.42M-$21.11M-$12.45M
Capital expenditures$542.0K$1.01M$284.0K-------
Free cash flow-$1.20M$3.19M-$9.70M-------
Investing cash flow-$8.54M-$4.87M-$3.04M-$2.40M$311.0K$3.21M-$4.75M$12.72M$14.50M-$1.64M
Financing cash flow$4.25M$7.35M$11.34M$16.15M-$2.18M$63.32M$21.09M$22.00M-$2.16M$80.2K
Stock-based compensation$1.82M$1.29M$932.0K$315.0K$943.0K$475.0K$4.95M$4.39M$7.17M$10.35M
Depreciation and amortization$2.19M$2.18M$1.44M$576.0K$668.0K$834.0K$788.0K$650.1K$514.4K$762.4K

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-31.8%21.4%14.8%17.6%-0.4%1.5%-3.3%10.6%--
Gross margin16.9%17.2%10.4%5.6%-3.9%4.4%4.6%-2.5%6.5%-
Operating margin-6.8%0.6%-8.0%-23.0%-49.0%-45.7%-56.3%-51.2%-45.2%-
Net margin-7.7%-0.5%-10.1%-25.7%-52.8%-49.7%-55.7%-50.7%-45.2%-
Free cash flow margin-1.7%3.1%-11.6%-------
Return on equity-14.4%-1.5%-39.6%-132.4%-1288.9%-90.4%-168.0%-117.8%-78.8%-37.4%
Return on assets-9.3%-0.8%-16.2%-40.1%-67.3%-39.7%-77.0%-61.1%-44.1%-23.8%
Current ratio3.982.631.732.001.685.432.983.555.347.74
Debt to equity0.240.260.390.658.110.610.000.00--

Source: XBRL data Rockwell Medical Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-11, first reported May 16, 2022.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

RMTI peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
RMTI$69.39M-21.1%-$5.08M-7.3%$30.3M
LLY$86.46B+45.5%$27.58B31.9%$1.33T
JNJ$99.33B+7.8%$16.09B16.2%$679.13B
ABBV$66.01B+10.7%$10.34B15.7%$518.44B
MRK$67.38B+4.9%$2.45B3.6%$366.73B
NVS$54.53B+8.4%$13.98B25.6%$312.35B
AZN$58.74B+8.6%$10.22B17.4%$293.69B
ABT$48.23B+10.0%$4.70B9.7%$191.40B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$183.23B

RMTI FAQ

8 questions
  • What is RMTI revenue?
    Rockwell Medical Inc. (RMTI) reported $69.39M of revenue for the twelve months ended Jun 30, 2026. That is down 21.1% from the year before. Revenue for fiscal 2025 was $69.26M.
  • Is RMTI profitable?
    No. Rockwell Medical Inc. reported a net loss of $5.08M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does RMTI have?
    Rockwell Medical Inc. reported $10.52M in cash and cash equivalents and $9.00M of debt on its most recent balance sheet in SEC filings.
  • How fast is RMTI revenue growing?
    Rockwell Medical Inc.'s revenue changed -31.8% in fiscal 2025, to $69.26M. Its compound annual growth rate was +2.2% over 5 years.
  • What is RMTI gross margin?
    Rockwell Medical Inc.'s gross profit was $12.29M on $69.39M of revenue for the twelve months ended Jun 30, 2026, a gross margin of 17.7%.
  • What is RMTI free cash flow?
    Rockwell Medical Inc. generated $1.54M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of $2.90M less capital expenditures.
  • When did RMTI last report financial results?
    The latest statements here come from Rockwell Medical Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.
  • Where does this RMTI financial data come from?
    Quantisnow builds these statements from the structured XBRL data Rockwell Medical Inc. files with the SEC. It is provided for information only and is not investment advice.